Emibetuzumab
CAS No. 1365287-97-3
Emibetuzumab( —— )
Catalog No. M36695 CAS No. 1365287-97-3
Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 223 | Get Quote |
|
| 5MG | 425 | Get Quote |
|
| 10MG | 677 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEmibetuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEmibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.
-
DescriptionEmibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer.
-
In VitroEmibetuzumab (LY2875358) (100 nmol/L; 6 days) inhibits HGF-stimulated proliferation of H596.Cell Proliferation Assay Cell Line:H596 cells (HGF-stimulated) Concentration:100 nmol/L Incubation Time:6 days Result:Suppressed cell proliferation.
-
In VivoEmibetuzumab (LY2875358) (10 mg/kg; i.v.; once a week for 5 weeks) inhibits in vivo growth of glioblastoma U87MG xenograft tumors in mice.Emibetuzumab (10 or 20 mg/kg; i.v.; single) downregulates levels of MET and pMET in the tumors of mice.Emibetuzumab (10 mg/kg; i.v.; once a week for 3, 5 or 6 weeks) exhibits antitumor effects on MET-amplified xenograft mouse tumor models.Animal Model:Athymic nude mice (U87MG tumor xenograft model).Dosage:10 mg/kg Administration: Intravenous injection, once a week for 5 weeks.Result:Demonstrated a significant inhibition of tumor growth.Animal Model:Athymic nude mice (MKN45 xenograft tumor model).Dosage:10 or 20 mg/kg Administration:Intravenous injection, single.Result:Reduced MET and pMET in the tumors by approximately 50% at both the 10 and 20 mg/kg doses by 72 hours post dose, and the reductions persisted to 14 days.Animal Model:Athymic nude mice (MET-amplified xenograft mouse tumor models).Dosage:10 mg/kg Administration:Intravenous injection, once a week for 3, 5 or 6 weeks. Result:Resulted in a marked reduction in tumor growth in the MKN45/SNU-5/EBC-1 gastric xenograft tumors.
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met/HGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1365287-97-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Liu L, et al. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth. Clin Cancer Res. 2014 Dec 1;20(23):6059-70. ?
molnova catalog
related products
-
Tepotinib hydrochlor...
Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations.
-
MGCD-265
MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively.
-
BMS-794833
BMS794833?is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM.
Cart
sales@molnova.com